DocumentsDate added
Research article:-
Yuanqing Tu1, Feng Huang2, Saichun Wu1, Manping Li1, Jing Zeng1 & Xiaoyun Tong3*
1 Bachelor,2Ph.D, Pharmacy college of Jinan University,Guangzhou,P.R.China,510632, 3*M.D, Teaching & Research Section of Internal Medicine of Traditional Chinese Medicine, College of Clinical Medicine, Yunnan University of TCM, Kunming, P.R.China, 650021.
Abstract :- The purpose of this research is to explore the effect of ferulic acid in myocardial infarction rats induced by Isoproterenol. The rats were divided into control, model, simvastatin, ferulic acid (Low, Middle, High dose) groups. Control and model groups were orally pretreatment with saline for 21 days, Simvastatin group with simvastatin(15mg/kg), and ferulic acid with ferulic acid (10, 20 and 40mg/kg, respectively), and then all the groups were subcutaneously injected with isoproterenol except control group on 19th, 20th, 21st days at an interval of 24h to induce myocardial infarction model. Lead II electrocardiograph were observed and recorded. Cardiac marker enzymes in serum were detected. The model group rats showed increase in the level of lactate dehydrogenase, creatine kinase and malondialdehyde and decrease in the activities of superoxide dismutase. Pretreatment with ferulic acid can restore the level of marker enzyme to nearly normal. And the infarction size was also detected by TTC assay, the number of EPCs in peripheral blood was calculated by flow cytometry, the CD34+ cells and RBPJK protein in the cardiac tissue were evaluated with immunohistochemistry, the expression of Notch1 receptor and Jagged1 ligand were detected by western blotting. Pretreatment with ferulic acid can reduce the infarction size of rats and ameliorate the injury tissues. We can also observe higher percentage of EPCs in peripheral blood. Ferulic acid can up-regulates the level of Notch1 and Jagged1 compared with model group.
Key Words:- Ferulic Acid, Endothelial progenitor cells, Notch signaling pathway.
References:-
1.Zhi-Tang Chang, Lang Hong, Hong Wang, et al. Application of peripheral-blood-derived endothelial progenitor cell for treating ischemia-reperfusion injury and infarction:a preclinical study in rat model[J].Journal of Cardiothoracic Surgery2013; 8:33.
2.Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis[J]. Science 1997; 275(5302):964-7.
3.Mannarino E, Pirro M. Endothelial injury and repair: a novel theory for atherosclerosis. Angiology 2008; 59(2 Suppl):695-725.
4.Real C, Caiado F, Dias S. Endothelial progenitors in vascular repair and angiogenesis: how many are needed and what to do? Cardiovasc Hematol Disord Drug Targets 2008; 8(3): 185-93.
5.Raphael K. Notch signaling[J].Cold Sring Harbor Perspectives in Biology 2013:1-4.
6.Sang-Mo Kwon, Masamichi Eguchi, Mika Wada, et al. Specific Jagged-1 Signal From Bone Marrow Microenvironment Is Required for Endothelial Progenitor Cell Development for Neovascularization. Circulation 2008; 118: 157-65.
7.Karthikeyan K, Sarala Bai BR, Niranjali Devaraj S,et al. Cardio-protective effect of grape seed proanthocyanidins on isoproterenol-induced myocardial injury in rats. Int J Cardiol 2008; 115(3):326-33.
8.Karthikeyan K, Sarala Bai BR, Niranjali Devaraj S,et al. Grape seed proanthocyan-idins ameliorates isoproterenol-induced myocardial injury in rats by stabilizing mitochondrial and lysosomal enzymes:an in vivo study. Life Sci 2007; 81(23-24):1615-21.
9.Claus P, Weidemann F, Dommke C, et al. Mechanisms of postsystolic thickening in ischemic myocardium :mathematical modeling and comparison with experimental ischemic substrates.Ultra-soud Med Biol 2007;33(12):1963-70.
10.Karanu FN, Murdoch B, Gallacher La, et al. The Notch ligand jagged1 represents a novel growth factor of human hematopoietic stem cells[J]. J Cell Biochem 2007; 101(3):767-84.
Copyright © 2013 Xiaoyun Tong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
*Correspondence address:
Xiaoyun Tong M.D,
Teaching & Research Section of Internal Medicine of Traditional Chinese Medicine, College of Clinical Medicine, Yunnan University of TCM, Kunming, P.R.China, 650021.
Original article:- Medical Microbiology,
Abebe Mazengia, Gizachew Yismaw, Belay Anagaw & Chandrashekhar Unakal*
Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Ethiopia.
Abstract:-
Objective: The aim of this study was to determine Seroprevalence and associated risk factors of Hepatitis B and C virus among people attending the HIV VCT center. Methods: A cross-sectional study was conducted from January 2011 to March 2012 at Deber Markos Referral Hospital, Northwest Ethiopia. Systematic random sampling technique was applied to select the study participants and the total sample size was 423. The serum was checked for Hepatitis B and C virus markers by rapid test followed manufacturer instructions assay. Data was entered and analyzed using SPSS software package (version 16). Differences in proportions were evaluated by Pearson’s chi-square; p< 0.05 was considered to be significant. Results and Conclusion: A total of 423 voluntary counseling and testing (VCT) clients were examined for HBsAg and HCV viruses. HBV was detected in 24 (5.7%), HCV 6 (1.4%) and co-infection 1(0.2%). In conclusion, this study shows a high prevalence of HBV (5.7%) and HCV (1.4%) infection in clients of the VCT center. By considering this we recommend that screening of HBV infection is necessity with HIV in VCT center.
Key words:- Hepatitis B virus, Hepatitis C virus, HIV voluntary counseling and testing center.
References:-
1.Dienstage JL. Hepatitis B virus infection. N Engl J Med. 2008; 359:1486-1500.
2Gunn RA, Murray PJ, Ackers ML. Screening for chronic hepatitis B and C virus’s infections in an urban sexually transmitted disease. Sex. Tranm Dis.2001; 28:166-70.
3.Colin WS, Edgar PS, Lyn Finelli, Anthony E. Fiore, Beth P. Bell. Epidemiology of Hepatitis B Virus Infection. Epidemiol. 2006; 28:112–125.
4.Drosten C, Nippraschk T, Manegold C, Meisel H, Brixner V, Roth WK, et al. Prevalence of Hepatitis B virus DNA in anti-HBC positive /HBsAg- negative sera correlates with HCV but not HIV serostatus. J.Clin Virol. 2004; 29:59-68.
5.Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006; 44:6-9.
6.Finlayson MDC, Hayes PC, Simpson KJ. Diseases of the liver and biliary system: Churchill Living stone. London 1999; 5: 706-15.
7.Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244:359–362.
8.Xia GL, Liu CB, Cao HL. Prevalence of hepatitis B and C virus infections in the general Chinese population from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D and E virus infections in China. Int Hepatol Comm. 1996; 5: 62–73.
9.Chowdhury A, Santra A, Chaudhuri S. Hepatitis C virus infection in the general population: a community-based study in West Bengal, India. Hepatology 2003; 37: 802–09.
10.El-Hazmi MM. Prevalence of HBV, HCV, HIV-1, 2 and HTLV-I/II infections among blood donors in a teaching hospital in the central region of Saudi Arabia. Saudi Med J. 2004; 25: 26–33.
11.Di Bisceglie AM. Hepatitis C. Lancet 1998; 351:351–5.
12.HJ, Holland PV, Morrow AG, Purcell RH, Feinstone SM, Moritsugu Y. Clinical and serological analysis of transfusion associated hepatitis. Lancet 1975; 2:838–841.
13.Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005; 34:1329–39.
14.Thio CL, Seaberg EC, Skolasky R Jr. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study. Lancet 2002; 360: 1921–26.
15.World Health Organization (2009) Hepatitis. Fact sheet no.164. (Accessed in January 2011). http://www.thebiomedicapk.com.
16.Desta B, Kefenie H, Abebe A,Conti S, Pasquini P. Prevalence of hepatitis B infection among hospital personnel in Addis Ababa, Ethiopia. Eur J Epid.1989; 5:462-7.
17.Shimelis T, Torben W, Medhin G, Tebeje M, Andualm A, Demessie F, Mulu A et al. Hepatitis B virus infection among people attending the voluntary counseling and testing centre and antiretroviral therapy clinic of St Paul’s General Specialized Hospital, Addis Ababa, Ethiopia. Sex Transm Infect. 2008; 84:37–41.
18.Asfaw N, Zufan S, Girmay M. Prevalence of Hepatitis B surface antigen (HBsAg) among visitors of Shashemene General Hospital voluntary counseling and testing center. BMC Research Notes 2011; 4:35.
19.Workenesh A, James N, Almaz A, Tsehaynesh M, Amare D, Fikre E, et al. Higher Prevalence of Anti-HCV Antibodies Among HIV-Positive Compared to HIV-Negative Inhabitants of Addis Ababa, Ethiopia. J Med Virol. 2002; 68:12–7.
20.Moges F, Kebede Y, Kassu A, Mulu A, Tiruneh M, Getu D, Solomon A, et al. Seroprevalence of HIV, hepatitis B infections and syphilis among street dwellers in Gondar city, Northwest Ethiopia. Ethiop.J.Health Dev. 2006; 20:160-5.
21.Tiruneh M. Seroprevalence of multiple sexually transmitted infections among antenatal clinic attendees in Gondar Health Center, Northwest Ethiopia. Ethiop Med J 2008; 46:359-66.
22.Abebe A, Nokes D, Dejene A, Enquselassie F, Messele T, Cutts F. Seroepidemiology of hepatitis B virus in Addis Ababa, Ethiopia. Epidemiol Infect. 2003; 131: 757–70.
23.Hajrullah F, Skender T. Prevalence of HBV and HCV among blood donors in Kosovo. J Virol. 2009; 6:21.
24.Valsa M, Christine B, Ernest D. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis. 2002; 2: 293–302.
25.Addisu A, Yayehyirad T, Zufan S, Techalew S. Prevalence and risk factors of Hepatitis C among individuals presenting to HIV testing centers, Hawassa city, Southern Ethiopia. BMC Research Notes 2011; 4:193.
26.Tessema B, Yismaw G, Kassu A, Amsalu A, Mulu A, Emmrich F, et al. Seroprevalence of HIV, HBV, HCV and syphilis infections among blood donors at Gondar University Teaching Hospital, Northwest Ethiopia: Declining trends over a period of five years. BMC infect dis.2010; 10: 7.
*Correspondence address:
Dr. Chandrashekhar G. Unakal.,
Department of Medical Microbiology University of Gondar, P.O. Box 196, Telephone +251-918-153665.
Copyright © 2013 Unakal C. G et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Review article:-
Priyanka Sharma1*, Kuldip S Sodhi2, Kusum Singla3, Nitin Tangri4, Rajesh Pandey5 & Jasbir Singh6
Affiliation:-
1-3, 5,6 Department of Biochemistry, M.M Institute of Medical Sciences & Research, Mullana, Ambala, Haryana, India.
4Department of Respiratory Medicine, M.M Institute of Medical Sciences & Research, Mullana, Ambala, Haryana, India.
Abstract:-
Leptin, the protein product of the ob gene, is a multifunctional peptide hormone, the circulating concentration of which is proportional to fat mass since adipocytes are the primary source of leptin. It has a major physiological influence on body weight and metabolism and is significantly increased in obesity leading to the concept of leptin resistance. Leptin has been shown to increase the overall sympathetic nerve activity, facilitate glucose utilization and improve insulin sensitivity. Furthermore, leptin is capable of regulating cardiac and vascular contractility too. Studies indicate that leptin has a permissive role, with leptin administration being effective in states of leptin inadequacy, and largely ineffective in states of leptin excess. In addition, hyperleptinemia correlates with hyperphagia, insulin resistance, obesity, hyperlipidemia and hypertension, independent of total adiposity. In this article, we describe how the identification of leptin by Friedman et al in 1994 has proved seminal in broadening our understanding of the mechanisms underlying neuroendocrine function, body weight, and energy homeostasis. Availability of leptin or smaller and more soluble leptin analogues for clinical studies in humans is further expected to significantly advance the understanding of the mechanisms underlying energy homeostasis in humans. This, in turn, may result in development of novel therapeutic approaches for obesity and other metabolic disorders.
Key Words:- Adipose tissue, Leptin, Obesity, Hormones, Disease.
References:-
1.Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32.
2.Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 1999; 130(8): 671-80.
3.Feng H, Zheng L, Feng Z, Zhao Y, Zhang N. The role of leptin in obesity and the potential for leptin replacement therapy. Endocrine 2012 Dec 29 (Epub ahead of print). PMID-23274948
4.Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E, Dardeno TA, Kim SY, et al. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab 2011; 301: E567-E584.
5.Ren J. Leptin and hyperleptinemia-from friend to foe for cardiovascular function. J Endocrinol 2004; 181: 1-10.
6.Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002; 26: 1407-33.
7.Considine RV. Human leptin: an adipocyte hormone with weight regulatory and endocrine functions. Semin Vasc Med 2005; 5(1): 15-24.
8.Bluher S, Mantzoros CS. Leptin in humans:lessons from translational research. Am J Clin Nutr 2009; 89(suppl): 991S-7S.
9.Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002; 324: 127-37.
10.Jequier E. Leptin signalling. Cell Signal 2002; 14: 655-63.
11.Scheer FA, Helton MF, Mantzoros CS, Shee SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci USA 2009; 106: 4453-8.
12.Mullington JM, Chan JL, VanDogen HP, Szuba MP, Samaras J, Price NJ, et al. Sleep loss reduces diurnal rhythm amplitude of leptin in healthy men. J Neuroendocrinol 2003; 15: 851-4.
13.Mantzoros CS, Moschos SJ. Leptin: in search of role(s) in human physiology and pathophysiology. Clin Endocrinol 1998; 6: 179-86.
14.Einollahi N, Dashti N, Nabatchian F. Serum leptin concentrations during the menstrual cycle in Iranian healthy women. Acta Med Iran 2010; 48: 300-303.
15.Kiess W, Petzold S, Topfer M, Garten A, Bluher S, Kapellen T, et al. Adipocytes and adipose tissue. Best Pract Res Clin Endocrinol Metab 2008; 22: 135-53.
16.Chan JL, Bluher S, Yiannakouris N, Suchard MA, Kratzsch J, Mantzoros CS. Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans. Diabetes 2002; 51: 2105-12.
17.Farooqi SI, O’Rahilly S. Leptin: a pivotal regulator of human energy homeostasis. Am J Clin Nutr 2009; 89(suppl): 980S-4S.
18.Wang J, Obici S, Morgan K, Barzilai N, Feng Z, Rossetti L. Overfeeding rapidly induces leptin and insulin resistance. Diabetes 2001; 50: 2786-91.
19.Flier JS, Ahima RS. Leptin. Annu Rev Physiol 2000; 62: 413-37.
20.Mantzoros CS, Ozata M, Negrao AB. Synchronicity of frequently sampled thyrotrophin (TSH) and leptin concentrations in healthy adults and leptin-deficient subjects: evidence for possible partial TSH regulation by leptin in humans. J Clin Endocrinol Metab 2001; 86: 3284-91.
21.Harris M, Aschkenasi C, Elias CF. Transcriptional regulation of the thyrotrophin-releasing hormone gene by leptin and melanocortin signaling. J Clin Invest 2001; 107: 111-20.
22.Nillini EA, Vaslet C, Harris M, Hollenberg A, Bjorbak C, Flier JS. Leptin regulates prothyrotrophin-releasing hormone biosynthesis. Evidence for direct and indirect pathways. J Biol Chem 2000; 275: 36124-33.
23.Toda C, Shiuchi T, Ckageyama H, Okamoto S, Coutinho EA, Sato T. Extracellular signal-regulated kinase in the ventromedial hypothalamus mediates leptin-induced glucose uptake in red type skeletal muscle. Diabetes 2013 Mar 25 (Epub ahead of print). PMID-23530005.
24.Greo AV, Mingrone G, Giancaterini A, Manco M, Morroni M, Cinti S, et al. Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes 2002; 51: 144-51.
25.Perez C, Fernandez – Galaz C, Fernandez – Agullo T, Arribas C, Andres A, Ros M, et al. Leptin impairs insulin signaling in rat adipocytes. Diabetes 2004; 53: 347-53.
26.Ahren B, Havel PJ. Leptin inhibits insulin secretion induced by cellular cAMP in a pancreatic B cell line (INS- 1 cells). Am J Physiol Regul Integr Comp Physiol 1999; 277: R959-66.
27.Lam NT, Cheung AT, Riedel MJ, Light PE, Cheeseman CI, Kieffer TJ. Leptin reduces glucose transport and cellular ATP levels in INS- 1 beta cells. J Mol Endocrinol 2004; 32: 415-24.
28.Seufert J, Kieffer TJ, Leech CA, Holz GG, Moritz W, Ricordi C, et al. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: implications for the development of adipogenic diabetes mellitus. J Clin Endocrinol Metab 1999; 84: 670-6.
29.Tuduri E, Marroqui L, Soriano S, Ropero AB, Batista TM, Piquer S, et al. Inhibitory effects of leptin on pancreatic alpha – cell function. Diabetes 2009; 58: 1616-24.
30.Hill JW, Elmquist JK, Elias CF. Hypothalamic pathways linking energy balance and reproduction. Am J Physiol Endocrinol Metab 2008; 294: E827-32.
31.Landry D, Cloutier F, Martin LJ. Implications of leptin in neuroendocrine regulation of male reproduction. Reprod Biol 2013; 13(1):1-14.
32.Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet 1998; 18: 213-5.
33.Matarese G, Moschos S, Mantzoros CS. Leptin in immunology. J Immunol 2005; 174: 3137-42.
34.Mancuso P, Gottschalk A, Phare S, Peters-Golden M, Lukacs NW, Huffnagle GB. Leptin-deficient mice exhibit impaired host defence in gram-negative pneumonia. J Immunol 2002; 168: 4018-24.
35.Karsenty G, Oury F. The central regulation of bone mass, the first link between bone remodeling and energy metabolism. J Clin Endocrinol Metab 2010; 95: 4795-4801.
36.Hamrick MW, Della Fera MA, Choi YH, Hartzell D, Pennington C, Baile CA. Injections of leptin into rat ventromedial hypothalamus increase adipocyte apoptosis in peripheral fat and in bone marrow. Cell Tissue Res 2007; 327: 133-41.
37.Gordeladze JO, Drevon CA, Syversen U, Reseland JE. Leptin stimulates human osteoblastic cell proliferation, denovo collagen synthesis, and mineralization: Impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem 2002; 85: 825-36.
38.Hamrick MW. Leptin and bone: a consensus emerging? BoneKEy-Osteovision 2007; 4: 99-107.
39.Unger RH, Orci L. Lipoapoptosis: its mechanism and its diseases. Biochemica Biophysica Acta 2002; 1585: 202-12.
40.Havel PJ. Role of adipose tissue in body- weight regulation: mechanisms regulating leptin production and energy balance. Proc Nutr Soc 2000; 59: 359-71.
41.Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M. Interactions between leptin and the human sympathetic nervous system. Hypertension 2003; 41: 1072-9.
42.Malmquist K, Ohman KP, Lind L, Nystrom F, Kahan T. Relationships between left ventricular mass and the renin- angiotensin system, catecholamines, insulin and leptin. J Int Med 2002; 252: 430-9.
43.Winnicki M, Somers VK, Accurso V, Phillips BG, Puato M, Palatini P, Pauletto P. Fish – rich diet, leptin, and body mass. Circulation 2002; 106: 289-91.
44.Anderson CM, Ren J. Leptin resistance and endothelial dysfunction in preeclampsia. Cell Mol Biol 2002; 48: OL323-OL329.
45.Bjorback C, El-Haschimi K, Frantz D, Flier JS. The role of SOCS- 3 in leptin signaling and leptin resistance. J Biol Chem 1999; 274: 30059-65.
46.Moon HS, Matarese G, Brennan AM, Chamberland JP, Liux, Fiorenza CG, et al. Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes 2011; 60: 1647-56.
47.Farooqi S. Insights from genetics of severe childhood obesity. Horm Res 2007; 68(s): 5-7.
48.Banks WA. Leptin transport across the blood- brain barrier: implications for the cause and treatment of obesity. Curr Pharm Des 2001; 7: 125-33.
49.Tu H, Kastin AJ, Hsuchou H, Pan W. Soluble receptor inhibits leptin transport. J Cell Physiol 2008; 214: 301-5.
50.Buyukbese MA, Cetinkaya A, Kocabos R, Guvan A, Tarakciogln M. Leptin levels in obese women with and without type 2 diabetes mellitus. Mediators Inflamm 2004; 13(5-6): 321-5.
51.Donahue RP, Prineas RJ, Donahue RD. Is fasting leptin associated with insulin resistance among non-diabetic individuals? The Miami Community Health Study. Diabetes Care 1999; 22: 1092-6.
52.Tasaka Y, Yanagiarwa K, Iwamoto Y. Human plasma leptin in obese subjects and diabetics. Endocr J 1997; 44: 671-76.
53.Schulze PC, Kratzsch J, Linke A, Schoene N, Adams V, Gulen S, et al. Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur J Heart Fail 2003; 5: 33-40.
54.Modan- Moses D, Ehrlich S, Kantey H, Dagan O, Pariente C, Esrahi N, et al. Circulating leptin and the perioperative neuroendocrinological stress response after paediatric cardiac surgery. Critical Care Medicine 2001; 29: 2377- 82.
55.Dotsch J, Wagner R, Groschl M, Schoof E, Harig F, Scharf J, et al. Cardiopulmonary bypass surgery does not further increase elevated serum leptin concentration after major surgery. Pediatric Critical Care Medicine 2001; 2: 36-9.
56.Phillips BG, Kato M, Narkiewicz K, Choe I, Somers VK. Increase in leptin levels, sympathetic drive and weight gain in obstructive sleep apnea. Am J Physiol Heart Circ Physiol 2000; 279: H234-7.
57.Testelmans D, Tamisier R, Barone-Rochette G, Baguet JP, Roux-Lombard P, Pepin JL, et al. Profile of circulating cytokines:impact of OSA, obesity and acute cardiovascular events. Cytokines 2013; 66(13): S1043-6.
58.Kelesidis T, Mantzoroz CS. The emerging role of leptin in humans. Pediatr Endocrinol Rev 2006; 3: 239- 48.
59.Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet 1998; 18: 213-5.
60.Paz-Filho G, Mastronardi C, Delibasi T, Wong ML, Licinio J. Congenital leptin deficiency: diagnosis and effects of leptin replacement therapy. Arq Bas Endocrinol Metabol 2010; 54: 690-7.
61.Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Aguri C, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness and neuroendocrine/ metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110: 1093-1103.
62.Coppari R, Bjorbaek C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov 2012; 11(9): 692-708.
63.Zadeh ES, Lungu AO, Cochran EK, Brown RJ, Ghany MG, Heller T, et al. The liver diseases of lipodystrophy:the long term effect of leptin treatment. J Hepatol 2013; 78(13): S168-82.
64.Kamran F, Rother KI, Cochran E, Safar Zadeh E, Gorden P, Brown RJ. Consequences of stopping and restarting leptin in an adolescent with lipodystrophy. Horm Res Paediatr 2012; 78(5-6): 320-5.
65.Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 2010; 152: 93-100
66.Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli Am, et al. Recombinant human leptin in women with hypothalamic amenorrhoea. N Engl J Med 2004; 351: 987-97.
67.Lucas A, Granada ML, Olaizola I, Castell C, Julian MT, Pellitero S, et al. Leptin and thyrotrophin relationship is modulated by smoking status in euthyroid subjects. Thyroid 2013 (Epub ahead of print). PMID-23528137.
68.Chan JL, Moschos SJ, Bullen J, Heist K, Li X, Kim YB, et al. Recombinant methionyl human leptin administration activates signal transducer and activator of transcription 3 signaling in peripheral blood mononuclear cells in vivo and regulates soluble tumour necrosis factor- alpha receptor levels in humans with relative leptin deficiency. J Clin Endocrinol Metab 2005; 90: 1625-31.
69.Monzillo LU, Hamdy O, Horton ES, Hedbury S, Mullooly C, Jarema C, et al. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res 2003; 11: 1048-54.
70.Rosenbaum M, Goldsmith R, Bloomfield D, Magnano A, Weimer L, Heymsfield S, et al. Low- dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 2005; 115: 3579-86.
*Correspondence address:
Priyanka Sharma.,
Department of Biochemistry,
M.M Institute of Medical Sciences & Research,
Mullana,Ambala,Haryana,India.
Copyright © 2013 Sharma Priyanka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article:-
Nuzulia Irawati*, Jamsari and Yan Wirasti.
Affiliations:-
Department of Parasitology, Medical Faculty of Andalas University,Indonesia.
Abstract :
Aim: To know the diversity of allelic type of MSP-1 block 2 among Plasmodium falciparum isolates collected in a mountain area and a coastal area in West Sumatera, Indonesia, and compare them in a mountain and coastal area. Methods: A total of 56 P. falciparum infected blood samples, which were collected from 27 patients attending a local health facilities in South Solok district is a mountain region and 29 patients attending a local health facilities in South Coastal district is a coastal region, West Sumatera, Indonesia were used in this study. The regions flanking the highly polymorphic characters, block 2 for MSP-1, were genotyped by allele-specific nested-PCR to analyse the population diversity of parasite. Sequence analysis of the polymorphic regions of MSP-1 was also conducted to identify allelic diversity in the parasite population. Results : Diverse allelic polymorphism of MSP-1 was identified in P. falciparum isolates from a mountain area and a coastal area in West Sumatera, Indonesia,West Sumatera, Indonesia and most of the infections were determined to be mixed infections. Sequence analysis of MSP-1 block 2 revelaled that 16 different alleles for MSP-1 (3 for K1 type, 2 for MAD20 type and 2 for RO33 type) were identified. Conclusion: Extensive genetic polymorphism with diverse allele type was identified in MSP-1 in P. falciparum field isolates from a mountain area and a coastal area in West Sumatera, Indonesia. A high level of mixed infections was also observed, as was a high degree of multiplicity of infection.
Key words:-Plasmodium falciparum, MSP-1 block 2, allelic types, mountain area, coastal area.
References:-
1. Arez AP, Snounou G, Pinto J, Sousa CA Modiano D, Ribeiro H, Franko AS, Aleves J, do Rosario VE. A clonal Plasmodium falciparum opulation in an isolated outbreak of malaria in the republic of cabo Verde. Parasitology 1999;118: 347-55.
2. Aubouy A, Migot-Nabias F, Deleron P. Polymorphism in two merozoite surface proteins of Plasmodium falciparum isolates from Gabon. Malar J 2003; 2: 12.
3. Babiker HA, Walliker D. Current views on the population structure of Plasm- modium falciparum: implication for control. Parasitol Today.1997; 13: 262-7.
4. Contamin H, Fandeur T, Rogier C, Bonnefoy S, Konate L. Tarpe JF, Mercereau-puija-lon O. Different genetic characteristics of Plasmodium falciparum isolates collected during successive clinical malaria episodes in Senegalese children. Am J Trop Med Hyg 1996;54: 632-3.
5. Edrissian GH, Afshar A, Sayedzadeh A, Mohsseni G, Satvat MT. Assessment of the response in vivo and in vitro of Plasmodium falciparum to sulphadoxine-pyrimethamine in the malarious areas of Iran. J Trop Med Hyg 1993;96: 237-40.
6. Eskandarian AA, Keshavarz H, basco LK, Mahboudi F. Do mutations in Plasmodium falciparum dihydropteroate synthase and dihydrofolate reductase confer resisteance to suplphadoxine-pyrimethamine in Iran? Trans R Soc Trop Med Hyg 2002;96: 96-8.
7. Ferreira MU, da Silva Nunes M, Wunderlich G. Antigenic diversity and immu-ne evasion by malaria parasite. Clin Diagn Lab Immunol 2004;11: 987-95.
8. Jafari S, Jellinek T, Aida AO, Peyerl-Hoffmann G, Heuschkel C, Valey AO, Christo –phel EM.Population structure of Plasmodium falciparum isolates during an epidemic in southern Mauritania. Trop med Int Health2001; 6: 761-6.
9. Montoya I, Maestre A, Carmona J, Lopes D, Do Rosario V, Blair S. Plasmo- dium falciparum: Diversity studies of isolates from two Colombian regions with different endemicity. Exp Parasitol 2003;104: 14-9.
10. Moore S A, Surgey EG, Cadwgan AM. Malaria vaccines: where are we and where are we going? Lancet Infect Dis 2002;2: 737-3.
11. Moorthy VS, Hill AV. Malaria vaccines. Br Med Bull 2002;62: 59-72.
12. Phillips RS. Current status of malaria and potential for control. Clin Microbiol Rev 2000;14: 208-26.
13. Raj DK, Das BR, Dash AP, Supakar PC. Genetic diversity in the msp1 gene of Plasmodium falciparum in different malaria endemic localities. Am J Trop Med Hyg 2004;71: 285-9.
14. Sallenave-Sales S, Daubersies P, Mercereau-Puijalono O, rahimalala L, Contamin H; Druilhe P, Daniel-Ribeiro CT, Ferreira-da-Cruz MF. Plasmodium falcipa-rum: A comparative analysis of the genetic diversity in malaria-mesoendemic area of Brazil and Madagascar. Parasitol Res 2000;86: 692-8.
15. Taylor RR, Smith DB, Robinson VJ, Mc Bride JS, Riley EM. Human antibo-dy response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of immunoneoglobulin G3 subclass. Infect Immun1995; 63: 4382-8.
*Corresponding author:-
Nuzulia Irawati.,
Department of Parasitology,
Medical Faculty of Andalas University, Indonesia.
Copyright © 2013 Nuzulia Irawati, Jamsari and Yan Wirasti. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Short communication:-
Vela Desai1, Prena Pratik1* & Rajeev Sharma1**
Affiliation:-
1Prof & HOD, 1*PG Student,1**Senior Lecturer, Department of Oral medicine and radiology(OMR),Jaipur Dental College,Dhand, Amet, Thesil,Jaipur, Rajasthan, India.
Abstract :-
Recently, “Ergonomics” is being frequently used in the profession of dentistry. Good ergonomics is essential so that work capability, efficiency and high clinical level of treatment can be maintained throughout the working life of dental professionals. The scope of ergonomics in dentistry is large. Dentistry has always been known as an uneasy occupation therefore one must take into account the serious health hazards faced by the dentists. When talking about the musculoskeletal disorders it might be assumed that the knowledge of ergonomics may be of some use.
Key Words:- Ergonomics, dentists.
References:-
1.Pekka Kahri.Ergonomics and teamwork in dental treatment.PLANMECA OY 2005;1:1.
2.P. BUCKLE: ERGONOMICS AND MUSCULOSKELETAL DISORDERS,Occupational Medicine 2005;55:166.doi:10.1093/occmed/kqi081.
3.en.wikipedia.org[updated on 22 April 2013;cited on 2013 April 25 ]. Available from http://en.wikipedia.org/wiki/Systems_psychology.
4.Gupta S. Ergonomic applications to dental practice. Indian J Dent Res 2011;22:816-22.
5.Hill KB, Burke FJ, Brown J, Macdonald EB, Morris AJ, White DA, Murray K. Dental practioners and ill health retirement: A qualitative investigation into the causes and effects. Br Dent J 2010;209: E8.
6.R. Nutalapati, R. Gaddipati, H. Chitta, M. Pinninti, R. Boyapati: Ergonomics in Dentistry and the Prevention of Musculoskeletal Disorders in Dentists. The Internet Journal of Occupational Health. 2010 Volume 1 Number 1. DOI: 10.5580/c9b.
7.Occupational Safety and Health Administration, 29 CFR Part 1910. [Docket No. S-777],RIN No. 1218-AB36.[updated on November 14, 2000;cited on 24 April 2013]. Available from http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=federal_register&p_id=16305.
8.Third age. com[cited on 2013 April 25].Available from http://www.thirdage.com/hc/g/musculoskeletal-disorder-symptoms.
9.James B. Bramson, Scott Smith, Guido Romagnoli. Evaluating Dental Office Ergonomic Risk Factors And Hazards. J Am Dent Assoc 1998;129:174-183.
10.Technical Profile. Dental Operating Microscopes: Don’t Equip an Operatory Without One. Inside Dentistry 2007;5:2-4.
11.Public Services Health & Safety Association[updated on 30 April 2013;cited on 2013 January 25].Available from http://www.healthandsafetyontario.ca/HSO/ media/ PSHSA/ pdfS/ MSDs/MSDs.pdf.
12.INDIAN HEALTH SERVICE.ERGONOMICS RECOMMENDATIONS FOR DENTAL PROGRAMS [cited on 2013 Januruary 17]. Available from http://www.dentalclinicmanual.com/docs/Ergonomic_considerations.pdf.
13.Dr.Michael Dougherty. Ergonomics principles in dental setting: part 1[Cited on 2012 Janurary 13] Available from http://www.eugenol.com/attachments/0007/6874/papers_ergonomic_principles_part1.pdf.
14.Ergonomics and dental work. Occupational Health Clinics for Ontario Workers Inc. Available from http://www.ohcow.on.ca/uploads/Resource/Workbooks/ ERGONOMICS %20AND%20DENTAL%20WORK.pdf.
15.Selecting Ergonomically Sound Equipment. OSHA Program Manual for Dental Facilities.[Cited on 2013 Feb 12 ]Available from http://blogs.hcpro.com/osha/wp-content/uploads/2011/07/DOSPM2_7-8.pdf.
16.Priyanka Airen Sarkar, Anand L Shig. Ergonomics in General Dental Practice.People’s Journal of Scientific Research 2012 Jan;5(1):60.
*Correspondence address:
Dr.Prena Pratik,
PG Student,
Department of Oral medicine and radiology(OMR),
Jaipur Dental College, Dhand, Amet, Thesil, Jaipur, Rajasthan, India.
Copyright © 2013 Vela Desai,Prena Pratik & Rajeev Sharma. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.